Beta Bionics, Inc. (BBNX)

Beta Bionics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-77.84	-54.76	-44.1	-64.75
Depreciation & Amortization	2.47	2.28	2.09	2.09
Other Amortization	-	-	-	0.01
Loss (Gain) From Sale of Assets	0.02	0.02	0.01	0.04
Loss (Gain) From Sale of Investments	-2.65	-2.91	-0.75	-
Stock-Based Compensation	13.63	6.38	5.66	6.1
Provision & Write-off of Bad Debts	0.05	0.07	0.05	-
Other Operating Activities	18.28	12.78	9.9	-0.91
Change in Accounts Receivable	-4.13	-7.62	-4.49	-
Change in Inventory	-8.89	-11.44	-1.19	-
Change in Accounts Payable	1.51	1.52	0.72	-0.08
Change in Unearned Revenue	2.31	2.46	0.34	-0.18
Change in Other Net Operating Assets	-1.34	2.94	-0.68	-2.53
Operating Cash Flow	-56.58	-48.27	-32.45	-60.21
Capital Expenditures	-3.96	-3.4	-0.4	-0.77
Sale of Property, Plant & Equipment	-	0.05	0	0
Investment in Securities	-189.17	-0.13	-69.3	-
Investing Cash Flow	-193.13	-3.48	-69.69	-0.77
Issuance of Common Stock	213.85	0.1	0.03	0.39
Other Financing Activities	-2.81	-4.15	-	11.41
Financing Cash Flow	270.71	55.62	101.03	56.78
Net Cash Flow	21	3.87	-1.11	-4.2
Free Cash Flow	-60.53	-51.67	-32.85	-60.98
Free Cash Flow Margin	-68.34%	-79.34%	-273.84%	-34067.04%
Free Cash Flow Per Share	-1.94	-8.12	-6.19	-12.20
Levered Free Cash Flow	-43.43	-35.24	-19.66	-
Unlevered Free Cash Flow	-43.43	-35.24	-19.66	-
Change in Working Capital	-10.53	-12.15	-5.31	-2.79

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q